Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: Physician knowledge, patient adherence

被引:7
|
作者
Solem, Caitlyn [1 ]
Mody, Reema [2 ]
Stephens, Jennifer [1 ]
Macahilig, Cynthia [3 ]
Gao, Xin [1 ]
机构
[1] Pharmerit North Amer, Bethesda, MD 20814 USA
[2] Takeda Pharmaceut Int, Deerfield, IL USA
[3] Market Certitude Med Data Analyt, Parsippany, NJ USA
关键词
Gastroesophageal reflux disease; proton-pump inhibitors; survey; adherence; physicians; patients;
D O I
10.1331/JAPhA.2014.13117
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To describe physicians' knowledge, patients' adherence, and perceptions of both regarding mealtime-related dosing directions for proton-pump inhibitors (PPIs). Design: Chart review and survey of patients and physicians. Setting: United States, with data collected between January and July 2011. Participants: Patients being treated for gastroesophageal reflux disease (GERD) with PPIs and their prescribing physicians. Main outcome measures: Patient-and physician-reported perception of PPI mealtime-related directions as important/ inconvenient (seven-point Likert scale; 7 = very important/ very inconvenient); physician-reported knowledge of PPI mealtime-related dosing directions based on whether the agent is labeled to be taken 30-60 minutes before eating (DIR-esomeprazole magnesium [Nexium-AstraZeneca], lansoprazole, and omeprazole) or labeled to be taken regardless of meals (NoDIR-dexlansoprazole [Dexilant-Takeda], rabeprazole, and pantoprazole); and patient-reported PPI mealtime-related directions received and adherence to directions. Results: Physicians (n = 262) recruited 501 patients who had been prescribed PPIs (262 DIR/239 NoDIR; mean age 51 years, 37% men, 56% nonerosive GERD [29% undocumented]). Across PPIs, physicians frequently reported incorrect directions or "did not know directions" (29% for esomeprazole to 69% for pantoprazole). While 98% of patients reported receiving directions from their physicians and 55% from their pharmacists, only 65% of DIR patients and 18% of NoDIR received directions consistent with product labeling. Physicians perceived greater inconvenience than patients (4.4 vs. 1.6, P < 0.001) and greater importance (5.2 vs. 4.5, P < 0.001) of mealtime-related directions. Overall, 81% of patients reported taking their PPI as directed. Conclusion: While this patient cohort was adherent to directions given, physicians' directions were often inconsistent with product labeling. Understanding physician and patient knowledge gaps may be critical to ensuring patients receive appropriate directions, improving patient adherence to specific dosing instructions, attaining positive therapy outcomes, and identifying opportunities for pharmacist-led interventions.
引用
收藏
页码:144 / 153
页数:10
相关论文
共 50 条
  • [41] The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough
    Kiljander, TO
    AMERICAN JOURNAL OF MEDICINE, 2003, 115 : 65S - 71S
  • [42] Histology of symptomatic gastroesophageal reflux disease: Is it predictive of response to proton pump inhibitors?
    Miwa, Hiroto
    Takubo, Kaiyo
    Shimatani, Tomohiko
    Furuta, Takahisa
    Oshima, Tadayuki
    Tanaka, Junji
    Aida, Junko
    Ito, Masanori
    Kurosawa, Susumu
    Joh, Takashi
    Wada, Tsuneya
    Habu, Yasuki
    Watanabe, Yusuke
    Hongo, Michio
    Chiba, Tsutomu
    Kinoshita, Yoshikazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (03) : 479 - 487
  • [43] Comparative Safety and Efficacy of Proton Pump Inhibitors in Paediatric Gastroesophageal Reflux Disease
    Kierkus, Jaroslaw
    Oracz, Grzegorz
    Korczowski, Bartosz
    Szymanska, Edyta
    Wiernicka, Anna
    Woynarowski, Marek
    DRUG SAFETY, 2014, 37 (05) : 309 - 316
  • [44] COST ANALYSIS OF PROTON PUMP INHIBITORS IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE IN UKRAINE
    Iakovlieva, L.
    Gerasymova, O.
    Mishchenko, O.
    Bezditko, N.
    Kyrychenko, O.
    Kuznetsov, I
    VALUE IN HEALTH, 2015, 18 (07) : A623 - A624
  • [45] FACTORS AFFECTING EFFICACY OF GASTROESOPHAGEAL REFLUX DISEASE TREATMENT WITH PROTON PUMP INHIBITORS
    Lazebnik, L. B.
    Bordin, D. S.
    Masharova, A. A.
    Firsova, L. D.
    Silvestrova, S. Yu.
    TERAPEVTICHESKII ARKHIV, 2012, 84 (02) : 16 - 21
  • [46] Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease
    Shi, Yichao
    Li, Jianfeng
    Cai, Shuntian
    Zhao, Hong
    Zhao, Huijun
    Sun, Gang
    Yang, Yunsheng
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [47] Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors
    Hershcovici, Tiberiu
    Fass, Ronnie
    CURRENT OPINION IN GASTROENTEROLOGY, 2010, 26 (04) : 367 - 378
  • [48] Comparative Safety and Efficacy of Proton Pump Inhibitors in Paediatric Gastroesophageal Reflux Disease
    Jaroslaw Kierkus
    Grzegorz Oracz
    Bartosz Korczowski
    Edyta Szymanska
    Anna Wiernicka
    Marek Woynarowski
    Drug Safety, 2014, 37 : 309 - 316
  • [49] Efficacy and Safety of Proton Pump Inhibitors in the Management of Pediatric Gastroesophageal Reflux Disease
    Tjon, James A.
    Pe, Michael
    Soscia, Joanna
    Mahant, Sanjay
    PHARMACOTHERAPY, 2013, 33 (09): : 956 - 971
  • [50] Proton-pump inhibitors are the treatment of choice in acid-related disease
    Brunner, G
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 : S9 - S13